Overcoming Resistance to CDK4/6 Inhibitors - Metastatic Breast Cancer Trial Talk

Research News

The standard treatment for ER-positive, HER2-negative MBC is a combination of hormone therapy plus a CDK4/6 inhibitor: palbociclib (Ibrance®), ribociclib (Kisqali®), or abemaciclib (Verzenio®). However, over time, people often develop resistance to CDK4/6 inhibitors, which means the drugs stop working. Efforts are underway to predict who is likely to develop resistance before treatment begins and to overcome resistance after treatment has started.

Click the links below to learn about new strategies being studied in clinical trials to overcome resistance to CDK4/6 inhibitors.

CDK4/6 Inhibitor Resistance
Clinical Trials That Include CDK Inhibitors

Last Modified on October 2, 2023



for past articles or specific information.